Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Thiamylal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.51 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamylal SCHEMBL1666144 | 1.00 | MMP9 (0.79) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Thiamylal SCHEMBL34747 | 0.98 | MMP9 (0.77) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Thiamylal SCHEMBL1003375 | 0.93 | MMP9 (0.69) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL80734 | 0.89 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL8085730 | 0.89 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL41181 | 0.89 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL80735 | 0.89 | MMP9 (1.00) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL41182 | 0.87 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL7599361 | 0.87 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 | |
| Secobarbital SCHEMBL614906 | 0.87 | MMP9 (0.97) | MMP9LMNACYP3A4NR1I2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2160 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240099995-A1 | METHOD OF PREPARING A TOPICAL PHARMACEUTICAL COMPOSITION | PHEBRA PTY LTD (AU) | 2024-03-28 | — | — | US | claimed |
| US-20230293549-A1 | INTRAVENOUS GANAXOLONE FORMULATIONS AND METHODS OF USE IN TREATING STATUS EPILEPTICUS AND OTHER SEIZURE DISORDERS | MARINUS PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | claimed |
| US-20230074763-A1 | IDENTIFICATION OF HOST-TARGETING MODULATORS OF BACTERIAL UPTAKE AND ASSAY FOR QUANTIFYING INTRACELLULAR BACTERIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2023-03-09 | — | — | US | claimed |
| US-20220211621-A1 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | TLC BIOPHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | claimed |
| US-20210353751-A1 | COMBINATION THERAPIES FOR TREATMENT OF INFLAMMATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-18 | — | — | US | claimed |
| US-20210205248-A1 | GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-08 | — | — | US | claimed |
| WO-2021050532-A1 | COMPOSITIONS FOR TREATING FUNGAL INFECTIONS | AFYX THERAPEUTICS A/S (DK) | 2021-03-18 | — | — | WO | claimed |
| EP-3753410-A2 | COMBINATIONS COMPRISING GABA AGONISTS IN TREATMENT OF HYPERGLYCEMIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-12-23 | — | — | EP | claimed |
| US-5288498-A | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1994-02-22 | — | — | US | claimed |
| US-5288497-A | Compositions of oral dissolvable medicaments | THE UNIVERSITY OF UTAH (US) | 1994-02-22 | — | — | US | claimed |
| EP-0487520-A4 | COMPRESSED POWDER MEDICAMENTS | — | 1992-08-12 | — | — | EP | claimed |
| EP-0490916-A4 | COMPOSITIONS AND METHODS OF MANUFACTURE OF ORAL DISSOLVABLE MEDICAMENTS | — | 1992-08-12 | — | — | EP | claimed |
| EP-0490916-A1 | COMPOSITIONS AND METHODS OF MANUFACTURE OF ORAL DISSOLVABLE MEDICAMENTS. | UNIV UTAH RES FOUND (US) | 1992-06-24 | — | — | EP | claimed |
| EP-0487520-A1 | COMPRESSED POWDER MEDICAMENTS. | ANESTA CORP (US) | 1992-06-03 | — | — | EP | claimed |
| WO-1991003237-A1 | COMPOSITIONS AND METHODS OF MANUFACTURE OF ORAL DISSOLVABLE MEDICAMENTS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-21 | — | — | WO | claimed |
| WO-1991003099-A1 | COMPRESSED POWDER MEDICAMENTS | ANESTA CORPORATION (US) | 1991-03-07 | — | — | WO | claimed |
| US-4863737-A | TRANSMUCOSAL DELIVERY | UNIVERSITY OF UTAH (US) | 1989-09-05 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |